Eiger BioPharmaceuticals Announces Phase 2 LIBERTY Study in Pulmonary Arterial Hypertension Did Not Meet Primary Endpoint

Stock Information for Eiger BioPharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.